Small molecule therapeutics targeting S2R have exhibited increasing success in amelioration of pathology observed in Alzheimer’s disease, including restoration of membrane trafficking, synaptic plasticity, synaptic density, and memory ability, primarily via displacing the binding of toxic amyloid-β oligomers. This evidence concerns the gene TMEM97 and early-onset autosomal dominant Alzheimer disease.